Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23471 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Audrey Pelletier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi Genzyme.
Abstract (Originalsprache)
Background
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with a high rate of disease recurrence following endoscopic sinus surgery (ESS). Type 2 disease is associated with a higher incidence of recurrence and is believed to impact disease resolution via interference with epithelial healing and pathogen immunity. We wished to verify if perioperative control of Type 2 inflammation with an anti‐IL4/IL13 targeting monoclonal antibody and during the resolution period following surgery leads to better control of the disease long term.
Methods
In this prospective, placebo‐controlled, double‐blinded trial. Thirty adult subjects with recurrent CRSwNP underwent ESS plus or minus 14 weeks of perioperative dupilumab, initiated 4 weeks (two injections) pre‐ESS. Subjective and objective parameters of nasal patency, olfaction, quality of life (QoL), and adverse events were monitored up to 52 weeks post‐ESS. Microbiological culture was performed to characterize pathogens colonization under both conditions.
Results
ESS safely improved subjective and objective measures of nasal patency, olfaction, and QoL in both groups. Olfaction was conserved longer in the dupilumab‐treated group, with 33.3% of subjects presenting anosmia at 12 months after ESS in the dupilumab group compared to 50.0% with placebo. This was associated with persistent decreases in serum IgE, which were not seen with placebo treatment. No unusual safety signals were observed.
Conclusion
Short‐course adjuvant perioperative treatment with dupilumab is associated with improved long‐term olfactory outcomes and persistent lowering of serum IgE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
- Canadian Center for Computational Genetics, McGill University, Montreal, Quebec, Canada.
- Division d'Oto-rhino-laryngologie et chirurgie cervico-faciale du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
ORCID-Profile: Martin Desrosiers
Förderung
- Sanofi Genzyme
Zitieren
APA
Pelletier, A., Endam, L. M., Gonzalez, E., Jannat, S., Irani, T., & Desrosiers, M. (2025). Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23471
Vancouver
Pelletier A, Endam LM, Gonzalez E, Jannat S, Irani T, Desrosiers M. Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23471
BibTeX
@article{Pelletier2025,
author = {Pelletier, Audrey and Endam, Leandra Mfuna and Gonzalez, Emmanuel and Jannat, Sheherazade and Irani, Thea and Desrosiers, Martin},
title = {Perioperative adjuvant therapy with short course of dupilumab with ESS for recurrent CRSwNP},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23471}
}
EUVIMED